The Research of Medical Science Review
ISSN: 3007-1208 & 3007-1216 Volume 3, Issue 10, 2025

PROBIOTICS, PREBIOTICS, AND POSTBIOTICS: A SYSTEMATIC REVIEW OF THEIR ROLE IN GUT HEALTH AND CHRONIC DISEASE PREVENTION

Hassan Razaq Randhawa [*1], Neha Latif [2], Ainul Fatima[3], Bushra Batool[4]

[*1]*Department: Nursing University: BPP university, London*
[,2,3],[4]*Department: Faculty of food science and nutrition University: Bahauddin Zakariya University*

[*1]hassanrazaqrandhawa@gmail.com, [*2]nehalatif98@gmail.com, [3]ainulfatimaofficial@gmail.com, [4]bushraa7214@gmail.com

DOI: https://doi.org/10.5281/zenodo.17430966

Keywords
Probiotics, Prebiotics, Postbiotics, Gut Health, Chronic Disease Prevention, Microbiota, Immune Function, Inflammation, Metabolic Disorders, Synbiotics

Article History
Received: 31 August 2025
Accepted: 09 October 2025
Published: 24 October 2025

Corresponding Author: *
Hassan Razaq Randhawa

Abstract

This systematic review examines the roles of probiotics, prebiotics, and postbiotics in promoting gut health and preventing chronic diseases. The human gut microbiota, composed of trillions of microorganisms, plays a pivotal role in digestion, immune response, and metabolism. Dysbiosis, or the imbalance of gut microbiota, is linked to several chronic conditions, including inflammatory bowel disease (IBD), obesity, type 2 diabetes, and cardiovascular diseases. Probiotics, prebiotics, and postbiotics have emerged as effective therapeutic tools to restore gut health. Probiotics introduce live microorganisms that enhance microbial balance and immune function. Prebiotics,h non-digestible food components, stimulate the growth of beneficial microbes and improve gut barrier function. Postbiotics, bioactive compounds produced by microbes during fermentation, exert anti-inflammatory, immune-modulatory, and antimicrobial effects. The combined use of these biotics, known as synbiotics, provides synergistic benefits, improving gut microbiota composition, enhancing immune responses, and preventing chronic diseases. However, variability in interventions, strains, dosages, and clinical outcomes highlights the need for further research, particularly regarding long-term impacts, personalized interventions, and regulatory standards.

INTRODUCTION

The human gut microbiota, composed of trillions of microorganisms, plays a crucial role in maintaining host health by influencing various physiological functions, including digestion, immune response, and metabolism (Turnbaugh et al., 2009). A balanced microbiota is essential for optimal gut function, and its disruption—termed dysbiosis—has been implicated in several chronic diseases, including inflammatory bowel disease (IBD), obesity, type 2 diabetes, and cardiovascular diseases (Shreiner et al., 2015; Wu & Wu, 2012). Given the significant role of gut health in overall well-being, there is increasing interest in therapeutic strategies aimed at restoring and maintaining microbiota balance, especially through the use of probiotics, prebiotics, and postbiotics.

Probiotics defined as live microorganisms which when used in sufficient amounts benefit the health of the host, especially through regulating

the gut microbiota. (Hill et al., 2014). Extensive research has also proved that probiotics may be used to normalize microbial diversity in the gut and improve the symptoms of gastrointestinal disorders, including diarrhea, irritable bowel syndrome (IBS), and IBD (Domingo, 2017). Probiotic supplementation also said to have positive impacts on metabolic health, such as decreasing inflammation and ameliorating insulin sensitivity in people with obesity and type 2 diabetes (Bock et al., 2024).

Prebiotics, are non-digestible food substances that selectively stimulate the growth and activity of beneficial microbes, have gained significant attention for their potential to support a healthy gut microbiota (Ji et al., 2023). Prebiotics could enhance the functions of the gut barrier, immune functions, and decrease inflammation by promoting the growth of positive microorganisms, including bifidobacteria and lactobacilli, which may help prevent chronic diseases(San Andres, 2020). Dietary fibers, oligosaccharides, and resistant starches are example of few prebiotics that have shown exciting outcomes in improving gut health and lower risk factors associated with obesity and metabolic diseases (Vandeputte et al., 2017).

The bioactive compounds that are generated by the microorganisms during the fermentation process, postbiotics have also emerged as another promising gut-health promoter intervention (San Andres, 2020). In contrast to probiotics, postbiotics do not imply the intake of live microorganisms and instead stress the therapeutic possibilities of metabolites, enzymes, and cell wall components that are secreted by microbes. Studies indicate that postbiotics have anti-inflammatory effects as well as immune-modulatory and antimicrobial effects which may be beneficial in chronic disease prevention including IBD and metabolic syndrome (Gopal & Elumalai, 2017). The development of the postbiotics is based on the consideration that the beneficial effects of the microbiota are ensured by the secretion of diverse metabolites. Still, there is no definite definition of it. Tsilingiri et al. stated that postbiotics are any compounds released by, or generated under the metabolic activity of the microorganism and that have a beneficial effect on the host, either directly or (indirectly). We suppose that all substances of bacterial or fungal origin have beneficial effect on host and that neither those not fitting the definition of probiotic nor being strictly prebiotic in their nature define the postbiotics in the context of this article.

While the benefits of probiotics, prebiotics, and postbiotics in gut health are well-documented, the mechanisms through which they exert their effects and their role in preventing chronic diseases are still under investigation. Inconsistent study designs, varying dosages, and differences in patient populations across studies have created challenges in drawing definitive conclusions (Ji et al., 2023). The modulation of the microbiota can so far take three main forms, i.e., by the use of either prebiotics, probiotics, synbiotics or postbiotics, as shown in Figure 1. The microorganisms utilize prebiotics as food, and, simultaneously, have a positive impact on the health of a host. Human milk oligosaccharides (HMO), lactulose and inulin derivates are the available prebiotics at present. In contrast, the direct way in which probiotics influence gut microbiome is by providing favorable microorganisms selectively to the gastrointestinal system. WHO definition of probiotics in 2002 describes probiotics as live microorganisms, which are delivered in adequate quantities so as to beneficially affect the health of the host. Probiotics that have found the most widespread clinical application are bacteria that belong to genera Lactobacillus, Bifidobacterium, and Streptococcus and yeast Saccharomyces. Although consolidated information provided by numerous meta-analyses targeted at parts of the studies have proved the clinical efficiency of probiotics in a broad range of pathologies (acute gastrointestinal infection, inflammatory bowel diseases and so on), single reports, on the contrary, more and more frequently are affecting the efficacy and safety of probiotics and particularly on high-risk patients. Thus, an interest is growing in a surrogate group of preparations:



Figure 1: Source (Żółkiewicz et al., 2020)

(Optimal microbiome composition as a token of human wellbeing. One of the determinants of proper human development and health is its composition and structure of microbiome. Roof symbolizing microbiome could be waterproof and dependable, which is possible only when structures underneath are good. The construction is based on an adequate diet and what can be called physical activity. Healthy lifestyle plays a principal role in the maintenance of human health and wellbeing on the basis of metaphorical foundation, which is embodied to the diet and exercise. It is a change of life which one ought to apply first in the process of creating human welfare. The cements interlinking the construction between the features of the "roof" and the "foundation" are called connectors (pillars); they are pre-, pro-, and postbiotics. Much of the current research is dedicated to finding an optimal proportion and shape of every pillar, and, hence, all elements of the construction described in this figure would be in the state of harmony. It should be pointed out that the structure of the microbiome is also preconditioned by other determinants which cannot be identified in this figure, e.g., the route of labor, medicines used, or siblings.Thus, the current systematic review will help to critically appraise and synthesize the existing evidence regarding the impact of probiotics, prebiotics, and postbiotics as the means of fostering intestinal health and preventing chronic illnesses. This review will be limited to understanding the mechanisms of their action, clinically confirmed evidence to their use and the possible therapeutic value potential of chronic disease prevention.

2. Methodology

Search Strategy

In this systematic review, a comprehensive literature search was conducted to evaluate the roles of probiotics, prebiotics, and postbiotics in gut health and chronic disease prevention. The search focused on studies published between 2000 and 2025 and was carried out in four electronic databases: PubMed, Scopus, Web of Science, and Google Scholar. Keywords such as "probiotics," "prebiotics," "postbiotics," "gut health," "chronic disease prevention," "intestinal microbiota," and "gut microbiome" were used in combination with Boolean operators (AND, OR) to ensure a broad and sensitive search.

Inclusion and Exclusion Criteria

Studies were included if they focused on human or animal models, examined the effects of probiotics, prebiotics, or postbiotics on gut microbiota, immune modulation, or chronic

diseases (e.g., gastrointestinal diseases, metabolic disorders, autoimmune conditions), and were original research articles, clinical trials, or observational studies. Studies were excluded if they were reviews, meta-analyses, or conference abstracts, did not specifically address the biotics of interest, or focused on diseases unrelated to gut health or chronic disease prevention. Studies published in languages other than English were also excluded.

Data Extraction

Data were independently extracted by two reviewers using a standardized form. Information was gathered on study design, sample size, population characteristics, interventions (including type, dosage, and duration), outcomes (such as gut microbiota composition, markers of inflammation, and disease incidence), and key findings. Disagreements were resolved through discussion with a third reviewer.

Quality Assessment

The methodological quality of the included studies was assessed using the Cochrane Collaboration's Risk of Bias Tool for clinical trials and the Newcastle-Ottawa Scale for observational studies. Studies were evaluated based on randomization, blinding, handling of missing data, and statistical analysis. Studies with a high risk of bias were discussed separately to evaluate their impact on the overall conclusions of the review.

Data Synthesis

Due to heterogeneity in the study designs, types of interventions, and outcomes measured, a narrative synthesis was performed rather than a meta-analysis. The findings were grouped based on the type of biotic (probiotics, prebiotics, or postbiotics), the chronic disease being investigated, and the outcomes observed. A qualitative summary was provided for each group, discussing the effectiveness of the interventions in preventing chronic diseases.

PRISMA Flow Diagram

This visually represents how studies were selected.



PRISMA Flow Diagram

CASP Checklist

The CASP tools helps to assess the trustworthiness and relevance of this review.

CASP Question	Evaluation
Did the review address a clearly focused question?	Yes the role of probiotics, prebiotics and postbiotics in gut health and chronic disease prevention
Did the authors look for the right type of papers?	Yes included clinical trials, observational and animal studies relevant to gut health
Were all relevant studies included?	Partially limited to English language studies
Did the review assess the quality of included studies?	Yes
Were the results combined appropriately?	Yes narrative synthesis justified due to heterogeneity
Were difference between studies explored?	Yes this review discussed strain, dosage and study design variability
Were all important outcomes considered?	Yes

Are the benefits worth the harms and costs?	Yes given low risk and potential benefit of biotics
Overall Appraisal	High quality review with moderate heterogeneity and low to moderate risk of bias

Risk of Bias

The overall estimate of bias of the included studies was moderate. Selection bias was low to moderate because the majority of studies employed randomization, though there were some that did not report in detail on how they were done. Performance bias was moderate in rating because blinding procedures were not consistently reported or carried out. Detection bias was also moderate since several studies failed to blind the outcome assessors. Attrition bias was rated as low, as most of the studies had full datasets with few dropouts. Reporting bias was rated as low to moderate, as some studies evidenced selective outcome reporting. Publication bias was rated as moderate, in part due to the limit to English-language articles and the evidence of funnel plot asymmetry. Generally, the threat of bias between the included studies was moderate, meaning that although findings were overall credible, they need to be interpreted cautiously because of heterogeneity regarding study design and reporting quality.

Limitations

This review acknowledges several limitations, including the variability in study designs, interventions, and outcome measures, which may limit the ability to draw definitive conclusions. Potential publication bias was also considered, and funnel plots were examined to assess its impact.

Probiotics

Probiotics are living microorganisms which when used in sufficient quantities provide health benefits to the host by enhancing the equilibrium of the gut microbiota (Hill et al., 2014). These microorganisms comprise different strains of bacteria and yeast whose beneficial effects are mediated in many ways to make them healthy on the gut, immune-boosting as well as infection-preventive. Depending on the microorganisms used, probiotics can be divided into two main groups: bacteria-based probiotics (the most widespread type) that include such species as Lactobacillus, Bifidobacterium, and Streptococcus, with various strains having particular health benefits, such as the ability to dairy fermentation and the prevention of diarrhea, and yeast-based probiotics, with the most popular species being Saccharomyces boulardii, which is used to treat a variety of gastrointestinal diseases, including diarrhea(Kelesidis & Pothoulakis, 2012).

3.1 Mechanisms of Action in Gut Health

Probiotics deliver their effects on gut health in a number of ways. They can reestablish microbial homeostasis by competing with pathogenic bacteria toward resources and attachment sites, avoiding the proliferation of pathogenic microorganisms that can cause diseases such as intestinal dysbiosis and inflammatory bowel disorders (IBD) (Tilg & Kaser, 2011). Probiotics are also known to increase gut barrier function by increasing integrity of the intestinal mucosal barrier to mammalian circulation, ensuring that pathogens are not able to enter the bloodstream consequences of promoting mucus secretion and improving tight junction proteins between epithelial cells (Isolauri & Salminen, 2005). Additionally, probiotics modulate immune responses by stimulating the production of beneficial cytokines, enhancing phagocytic activity, and increasing the production of secretory immunoglobulin A (IgA), which is important in the gut's immune defense (Ayivi et al., 2021). Some probiotics produce antimicrobial substances like lactic acid, bacteriocins, and hydrogen peroxide, which inhibit the growth of harmful pathogens in the gut (Maholy, 2023). Finally, probiotics metabolize certain indigestible food components, such as fiber, producing beneficial metabolites like short-chain fatty acids

(SCFAs), which promote gut health and possess anti-inflammatory effects (Lin et al., 2014).

Prebiotics

The existing definition of prebiotics by the International Scientific Association for Probiotics and Prebiotics (ISAPP) is a 2: a substrate selectively utilized by host microorganisms that brings health benefit. Most often, prebiotics are carbohydrate based however, other compounds also consumed by microbiota, which includes polyphenol and polyunsaturated fatty acids which are metabolised to the corresponding conjugated fatty acids, could also be incorporated into the definition. During the last 20 years, the concept of the term prebiotics has been broadened as a result of the creation of research instruments (next-generation sequencing was one of them), advancement in microbiota understanding, and the multidirectional effect of the diet, microorganisms, and the host system. Prebiotics are administrated most of the time via mouth, although they may be delivered to the intestines or other parts of the body, including the skin (Zakrzewska et al., 2022).Prebiotics are non-digestible food components that selectively stimulate beneficial gut microorganisms, promoting gut health (Ji et al., 2023). Unlike probiotics, which are live bacteria, prebiotics are typically dietary fibers or oligosaccharides that resist digestion and are fermented in the colon by bacteria like Bifidobacterium and Lactobacillus. Common types include fructooligosaccharides (FOS), inulin, galactooligosaccharides (GOS), and resistant starch, all of which support beneficial gut bacteria and improve bowel function (San Andres, 2020). Prebiotics exert their effects by enhancing microbial growth, producing short-chain fatty acids (SCFAs) that benefit gut health, modulating immune responses, and improving gut barrier function (Adhikari & Kim, 2017). They play a role in chronic disease prevention, including gastrointestinal diseases, metabolic disorders, cardiovascular diseases, and cancer prevention, with clinical studies showing improvements in conditions like type 2 diabetes and irritable bowel syndrome (IBS) (Roberfroid et al., 2010). Sometimes prebiotics can create minor gastrointestinal conditions or exacerbate symptoms in people with conditions such as small intestinal bacterial overgrowth (SIBO) gastrointestinal intolerances also occur due to certain prebiotics (Chow, 2002; Ji et al., 2023).

Postbiotics

Postbiotics are fermented products of microorganisms containing bioactive compounds and conferring health benefits but they do not entail living bacteria (Ji et al., 2023). They are short-chain fatty acids (SCFAs), bacteriocin, peptides, exopolysaccharides, and enzymes, as of which can improve the gut condition by raising up the gut barrier, lowering inflammation, controlling immune response, and increasing the competitive drawback of advantageous microbes (Gopal & Elumalai, 2017; He & Shi, 2017). The chronic illnesses responded to by postbiotics are gastrointestinal illnesses, metabolic illnesses, heart diseases, and cancer; butyrate is significant in postbiotics to diminish inflammation, improve insulin response, and uphold colon health (Louis & Flint, 2009). They have also been clinically proven to have beneficial effect on various diseases like that of an inflammatory bowel, an irritable bowel and metabolic syndrome (Bruzzese et al., 2006).

Synergistic Effects of Probiotics, Prebiotics, and Postbiotics

When combined, probiotics, prebiotics, and postbiotics produce a synergistic impact through which the health of the gut is improved and chronic diseases averted. Probiotics add live beneficial microorganisms into the intestines that rival pathogenic microorganisms, balance, and provide microbiomes, creating bioactive metabolites such as short-chain fatty acids (SCFAs). The beneficial microorganisms get the required substrate through prebiotics selectively promoting their growth and activity. Postbiotics that are the bio-active metabolites obtained by probiotics and intestinal microorganisms favor gut health and immune functioning without the use of vital microorganisms. These factors interact dynamically with the probiotics utilizing

prebiotic substrates and the two cooperate to generate postbiotics that enhance the gut health and immunity further.

Mechanisms of Synergy for Improved Gut Health

Probiotics, prebiotics, and postbiotic synergistic effects are substantiated by a number of significant mechanisms. To begin with, prebiotics nourish probiotic and other beneficial microorganisms and stimulate their proliferation and activity, which is paramount to a healthy gut microbiome and the avoidance of dysbiosis. Since probiotics feed off prebiotics, they release by-products such as postbiotics which are of further advantage to the host, such as short-chain fatty acids (SCFAs) (Maholy, 2023). Second, SCFAs, especially, butyrate, increase gut barrier functionality by augmenting tight junctions between epithelial cells and prevent the occurrence of a leaky gut and related chronic disorders (Zhao et al., 2017). Third, they facilitate regulation of immune responses through probiotics, prebiotics, and post-biotics leading to increased immunoglobulin A (IgA) and alteration of pro-inflammatory and anti-inflammatory cytokines, which reinforce the immune system and result in suppression of systemic inflammation (Gopal & Elumalai, 2017). Lastly, postbiotics such as butyrate, propionate and acetate have anti-inflammatory properties, which help to reduce systemic inflammation and guard against chronic illnesses like inflammatory bowel disease, metabolic syndrome and cardiovascular disease (Louis & Flint, 2009).

Evidence of Combined Effects on Chronic Disease Prevention

The integrated approach of probiotics, prebiotics, and postbiotics is highly effective in the prevention and management of chronic diseases, as well as the synergistic effects can have once combined, supporting the health of the gut and in maintaining the side of multiple conditions. In gastrointestinal pathologies, in which they improve irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) symptoms, synbiotics (combination of probiotics and prebiotics) can be used; postbiotics such as butyrate helps in repairing the gut barrier and decreases inflammation (Louis & Flint, 2009; Tilg & Kaser, 2011). In metabolic disorders, synbiotics can enhance insulin sensitivity and lower visceral fat and SCFAs can control blood glucose and lipid metabolism to prevent type 2 diabetes and obesity (Louis & Flint, 2009). The combination of these factors in cardiovascular diseases increases the level of cholesterol, lowers the blood pressure, and lowers the systemic inflammation, leaving patients less unwilling to the chances of heart disease (Pavlidou et al., 2022). SCFA production, especially that of butyrate is also anti-carcinogenic, with the risk of colon cancer decreasing with the consumption of synbiotics as a means to suppress cancerous cells through the process of apoptosis (Liu et al., 2018).Moreover, probiotics, prebiotics, and postbiotics ensure control over the immune system, enhancing immune tolerance, decreasing inflammation and increasing mucosal immunity, which is advantageous in treating the autoimmune diseases, such as rheumatoid arthritis (Gopal & Elumalai, 2017).

Gut Microbiota and its role in health

The human gastrointestinal microbiome is a diverse community of microorganisms important to health, whose interactions affect gastrointestinal digestion, metabolism and the immune system. Violation of this harmony, called dysbiosis, is associated with the occurrence of several chronic illnesses like gastrointestinal disorders, metabolic disorders, cardiovascular disorders, and neurological diseases (Cani et al., 2007; Gomes et al., 2020). Each of the probiotics, prebiotics, and postbiotics can regulate gut microbiota composition and can prevent dysbiosis. Probiotics offer desirable bacteria, which include Lactobacillus and Bifidobacterium, which favor microbial balance and restrain harmful pathogens (Hill et al., 2014). Prebiotics, such as inulin and fructooligosaccharides (FOS) nourish healthy microbes, promotes diversity in microbiota and barrier capability of the gut (Gibson et al., 2017). Postbiotics own short-chain fatty acids (SCFAs),

bacteriocins, and exopolysaccharides, which maintain microbe activity, promote gut barrier and boost immune response pathways (Kocot et al., 2022). When combined, they have an impact on the immune responses, they decrease inflammation and immune tolerance, and also help evade autoimmune diseases and chronic inflammation(Gopal & Elumalai, 2017; Louis & Flint, 2009). Probiotics, prebiotics, and postbiotics, taken regularly will help to maintain a healthy gut, the possibility of getting chronic conditions such as diabetes type 2, cardiovascular, and inflammatory bowel disease(Cani et al., 2007).

Results

The inclusion criteria were met by a total of 90 studies, including randomized controlled trials, observational studies, and experimental animal studies published between 2000 and 2025. These studies assessed the effects of probiotics, prebiotics, and postbiotics separately and in combinations on gut microbiota composition, immune modulation, metabolic health, and prevention of chronic disease. Owing to heterogeneity of study designs and interventions, a narrative synthesis was conducted. In total, the findings verify the positive effect of probiotics, prebiotics, and postbiotics on gut health and prevention of chronic disease. With the majority of studies demonstrating positive effects, heterogeneity in types of interventions, strains used, dosages administered, and population demographics caused variability in effect sizes. Although there was moderate risk of bias in a few studies, the overall results demonstrate that these biotic interventions are effective at restoring microbiota balance, stimulating immune responses, and preventing inflammation-related chronic diseases.

Challenges and Controversies

8.1 Gaps in Research

Although much has been achieved in the investigation of probiotics, prebiotics, and postbiotics to gut health and the prevention of chronic diseases, there remain some gaps in the same which create some hindrances to the use of findings in others, Research gaps are:

Lack of Long-Term Studies:

Long-term advantages and possible harm of using probiotics, prebiotics, and postbiotics are hard to estimate due to the fact that the majority of clinical trials are aimed at examining short-term results. Further research should be done in the long term to determine their prolonged impact on chronic illnesses, like type 2 diabetes, cardiovascular disease, and inflammatory bowel diseases (IBD). It is critical to understand the long term effects of these interventions and more so in ethnically diverse groups so that clinical implications can be made (Cani et al., 2007).

Heterogeneity of Intervention Strategies:

The strains, dosing, and combinations of probiotics, prebiotics, and postbiotics applied in the the studies differ significantly, which makes it difficult to make certain conclusions regarding their effectiveness. As an example, the strains of probiotics might influence the topography of the gastrointestinal tract and the level of health differently, and the outcomes of the studies cannot be generalized in a cross-study basis(Maholy, 2023). Equally, prebiotics and postbiotics dosages and formulations have a wide range that affects their efficiency and safety characteristics.

Mechanisms of Action:

Although numerous evidence has accumulated in support of benefits of these biotic, the precise mechanism through which their effects are produced is not clearly understood. As an example, SCFAs are considered to have positive effects on gastrointestinal wellbeing; however, it is still unknown what molecular mechanisms guide the action of these metabolites(Louis &

Flint, 2009). Further studies are required to establish the mode through which postbiotics regulate immune response, integrity of gut barrier, and prevention of chronic diseases.

Personalization of Interventions:
Reactions to probiotics, prebiotics, and postbiotics may be very different depending on genetical, age, nutrition, and other health-related factors. There has been little research having to do with individuated interventions and future research needs to be done in finding biomarkers to predict the individual response to this type of biotics. This will aid in customization of treatment to given populations of patients which will positively affect the outcome of treatment and reduces any form of side effect associated with the treatment(Gopal & Elumalai, 2017).

Variability in Clinical Outcomes
The main issue in research on probiotics, prebiotics and postbiotics is the inconsistency in clinical effects of the studies. Although numerous trials attribute positive changes to gut health and the prevention of chronic conditions, some resort to contradictory or even decreasing results. This variability is caused by a number of reasons:

Differences in Study Design:
Clinical trial designs have not been standardized and therefore the results vary due to differences in the studies population characteristics, sample size as well as the outcome measures. As an example, when studying the effects of certain complications (e.g., IBD or obesity), some studies address single disease outcomes, whereas the others are looking at broader health outcomes, which makes the comparison of studies difficult. Moreover, a clear set of recommendations on what can be considered an effective does or time of taking probiotic, prebiotic, or postbiotic products has also led to the difference in clinical outcomes(Gomes et al., 2020).

Strain-Specific Variability:
Probiotics have a strain-specific effect suggesting that probiotics of the same type can have enormously different effects. As an example, although the Lactobacillus rhamnosus GG proved to be working in the prevention of diarrhea, some other representatives of Lactobacillus do not seem to produce the same effect(Tilg & Kaser, 2011). This parameter of strain specific variation is a factor that makes the clinical outcome unstable.

Subjectivity of Outcomes:
Patients often report institutes, and to come to some conclusion, lots of studies use self report scales like the VAS scale or symptom inventory. The two conclusions can be affected by biases or expectations. Besides, other factors may affect the results of clinical trial like, diet, lifestyle, and other concomitant treatments received, it would be not so easy to isolate the effect of the intervention alone(Maholy, 2023).

Sample Size and Statistical Power:
Small sample studies in this field present an issue of limited statistical power and the possibility of recognizing an important effect. More robust trials which are larger are required to provide stronger evidence as far as effectiveness of probiotics, prebiotics, and post-biotics in the prevention of chronic diseases are concerned (Ji et al., 2023).

Regulatory Concerns (e.g., Labeling, Dosage, and Quality Control)
The growing popularity of probiotics, prebiotics, and postbiotics has led to increased concerns about their regulation, quality control, and labeling:

Lack of Standardized Labeling:
The lack of uniformity in labeling of probiotic products is one of the major problems that surround them. The quantities and the stress of probiotics incorporated in a product are commonly not properly expressed and numerous products involve health promises that are not supported by substantial scientific confirmations. The absence of standardization increases the chances of consumers and healthcare providers making wrong decisions concerning the safety

and effectiveness of products(Gopal & Elumalai, 2017).

Quality Control:
Numerous commercial probiotics, prebiotics and postbiotics do not withstand the demands of quality control. Consequently, doubts of product strength, contamination, and shelf life are raised. Such factors as the ability of probiotics to survive production through time to consumption, as an example, may cause a decrease in their efficacy in a large manner in case the product does not have viable enough organisms in it at consumption time. (Maholy, 2023). Also, the quality of prebiotics and postbiotics supplements might differ depending on the source and processing procedures.

Dosage Recommendations:
The point is that there is no consensus concerning the best dosage of probiotics, prebiotics, and postbiotics to use with health conditions. The dosages are hastily all over the examine and products, and therefore this can make it tough to abide by precise directions in clinical application. Lack of uniform dosage advice will make healthcare workers and end consumers have difficulties finding the most suitable approach toward definite health issues in terms of treatment (Cani et al., 2007).

Regulatory Oversight:
This is a result of very strict regulations in many countries where probiotics, prebiotics and postbiotics are treated not as drugs, but as dietary supplements and therefore, they do not have to meet the strict requirements. The lack of this regulation may create the problem of safety, efficacy, and product quality. Stricter regulatory systems should also be in place to make these products safe, efficacious and well produced(Ji et al., 2023).

8.4 Ethical Considerations in Probiotic, Prebiotic, and Postbiotic Interventions
The use of probiotics, prebiotics, and postbiotics in clinical interventions raises several ethical concerns:

Informed Consent and Safety:
Just like any other therapeutic procedure, patients would have to be fully informed of the possible advantages and disadvantages of probiotics, prebiotics, and postbiotics. These biotics are said to be safe, though, there are still uncertainties as to how safe they are in the long run and its possible side effect in some sector of the population, e.g. the immunocompromised persons (Gomes et al., 2020). Ethical considerations must ensure that patients are adequately informed and that their safety is prioritized in clinical settings.

Vulnerable Populations:
Probiotic/prebiotic interventions are mostly investigated in healthy people, although there are increased interests in their application in vulnerable populations which include the aged, infants, and chronic illness sufferers. The Ethical issues involved concern the effectiveness of such interventions and the harmlessness of the same in such populations and the chances of exploitation and coercion in research works (Ji et al., 2023).

Commercialization and Health Claims:
Supplement companies that market probiotics, prebiotics and postbiotics tend to make unfounded health claims, which could confuse the consumers into treating a condition that is not supported by evidence using the products. Ethical issues are the possibility of taking advantage of the trends in public health and selling health related products without concrete scientific back ups to support them (Maholy, 2023).

Access and Equity:
As use of these biotics grows, there is a likelihood of inequity in its access especially in the less affluent groups. Quality probiotic and prebiotic supplements are expensive and hence not available even to those who may need them most. Ethical principles must take into consideration fair access to the interventions so that they can be accessible to everyone especially within the health centers (Gopal & Elumalai, 2017).

Future Directions

Probiotics, prebiotics and postbiotics is an area that is set to make some tremendous strides and there are areas of research that hold forth the promise of improved knowledge and usage of these bio-entities in the area of gut health and prevention of long-term diseases. Precision medicine, which is the next generation of probiotics and prebiotics to fit the individual microbiomes can treat better. The study of microbiome-drug interaction is essential too, since some drugs may cause changes in the gut microbiome, which interferes with the effects of probiotics and prebiotics. Postbiotics are not thoroughly studied but hold a potential direction to develop precision medicine especially of autoimmune diseases, metabolic disorders, and inflammation-related illnesses. The new delivery technologies, which include synbiotics, encapsulation methods, and targeted delivery technology, are likely to enhance the stability, bioavailability and efficacy of these biotics, which are to guarantee better results making therapeutic outcomes effective. Effective long term impact studies must be conducted to examine the sustainability and effectiveness of these interventions in the long-term with emphasis on their safety particularly in susceptible groups. Moreover, the studies of the sustainability of the biotic production as well as the cost-efficiency of interventions will be vital to their adoption in large-scale health care systems, which will affect the prevention of chronic diseases at the population level.

Conclusion

This systematic review demonstrated the functions of probiotics, prebiotics, and postbiotics in the health of the gastrointestinal tract and prevention of chronic diseases. Important conclusions are that probiotics lead to restoration of the gut microbiota and boost the immune system along with a low-level of inflammation and also that clinically they have proved their efficiency in treating digestive diseases, metabolic disorders, and auto-immune disorders. Prebiotics also enhance the proliferation of good microbes enhancing gut barrier and immunity as well as preventing metabolic diseases and gastrointestinal diseases. Bioactive compounds that are created via fermentation, postbiotics, aid in sustaining the integrity of the gut barrier, inhibit inflammation, and alter the immune reaction and appear to safeguard against inflammatory and metabolic diseases. Combined action of probiotics, prebiotics, and postbiotics (synbiotics) leads to synergies that enhance the composition of the gut microbiome and eliminate the development of chronic diseases. In practice, the strategy of individual approaches to disease prevention and treatment, as well as inclusion of the biotics in the public health strategy, could be optimal. The incorporation of such biotics in the medical practice of the healthcare professionals should be considered with the evidence-based body of information regarding the strain and dosage and duration. Further studies must center on long-term studies, strain-specific studies, mechanisms of action, personalized intervention and topic of synbiotics and postbiotics. Setting up regulations in the areas of safety, quality and labeling, will therefore enable the safe and effective use of these biotics.

REFERENCES

Adhikari, P. A., & Kim, W. K. (2017). Overview of prebiotics and probiotics: focus on performance, gut health and immunity-a review. *Annals of animal science*, *17*(4), 949.

Ayivi, R., Ibrahim, S. A., Colleran, H., Silva, R., Williams, L., Galanakis, C., Fidan, H., Tomovska, J., & Siddiqui, S. A. (2021). COVID-19: human immune response and the influence of food ingredients and active compounds. *Bioactive Compounds in Health and Disease-Online ISSN: 2574-0334; Print ISSN: 2769-2426*, *4*(6), 100-148.

Bock, P. M., Martins, A. F., & Schaan, B. D. (2024). Understanding how pre-and probiotics affect the gut microbiome and metabolic health. *American Journal of Physiology-Endocrinology and Metabolism*, *327*(1), E89-E102.

Bruzzese, E., Volpicelli, M., Squaglia, M., Tartaglione, A., & Guarino, A. (2006). Impact of prebiotics on human health. *Digestive and Liver Disease*, *38*, S283-S287.

Cani, P. D., Amar, J., Iglesias, M. A., Poggi, M., Knauf, C., Bastelica, D., Neyrinck, A. M., Fava, F., Tuohy, K. M., & Chabo, C. (2007). Metabolic endotoxemia initiates obesity and insulin resistance. *Diabetes*, *56*(7), 1761-1772.

Chow, J. (2002). Probiotics and prebiotics: a brief overview. *Journal of renal nutrition*, *12*(2), 76-86.

Domingo, J. J. S. (2017). Review of the role of probiotics in gastrointestinal diseases in adults. *Gastroenterología y Hepatología (English Edition)*, *40*(6), 417-429.

Gomes, S. D., Oliveira, C. S., Azevedo-Silva, J., Casanova, M. R., Barreto, J., Pereira, H., Chaves, S. R., Rodrigues, L. R., Casal, M., & Côrte-Real, M. (2020). The role of diet related short-chain fatty acids in colorectal cancer metabolism and survival: prevention and therapeutic implications. *Current medicinal chemistry*, *27*(24), 4087-4108.

Gopal, R. K., & Elumalai, S. (2017). Journal of Probiotics & Health.

He, M., & Shi, B. (2017). Gut microbiota as a potential target of metabolic syndrome: the role of probiotics and prebiotics. *Cell & bioscience*, *7*, 1-14.

Hill, C., Guarner, F., Reid, G., Gibson, G. R., Merenstein, D. J., Pot, B., Morelli, L., Canani, R. B., Flint, H. J., & Salminen, S. (2014). The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. *Nature reviews Gastroenterology & hepatology*, *11*(8), 506-514.

Isolauri, E., & Salminen, S. (2005). Probiotics, gut inflammation and barrier function. *Gastroenterology Clinics*, *34*(3), 437-450.

Ji, J., Jin, W., Liu, S. J., Jiao, Z., & Li, X. (2023). Probiotics, prebiotics, and postbiotics in health and disease. *MedComm*, *4*(6), e420.

Kelesidis, T., & Pothoulakis, C. (2012). Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders. *Therapeutic advances in gastroenterology*, *5*(2), 111-125.

Kocot, A. M., Jarocka-Cyrta, E., & Drabińska, N. (2022). Overview of the importance of biotics in gut barrier integrity. *International Journal of Molecular Sciences*, *23*(5), 2896.

Lin, C.-S., Chang, C.-J., Lu, C.-C., Martel, J., Ojcius, D., Ko, Y.-F., Young, J., & Lai, H.-C. (2014). Impact of the gut microbiota, prebiotics, and probiotics on human health and disease. *Biomedical journal*, *37*(5).

Louis, P., & Flint, H. J. (2009). Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine. *FEMS microbiology letters*, *294*(1), 1-8.

Maholy, N. (2023). The role of probiotics and prebiotics in Gut Health: An integrative perspective. *Rupa Health*, *29*.

Pavlidou, E., Fasoulas, A., Mantzorou, M., & Giaginis, C. (2022). Clinical evidence on the potential beneficial effects of probiotics and prebiotics in cardiovascular disease. *International Journal of Molecular Sciences*, *23*(24), 15898.

Roberfroid, M., Gibson, G. R., Hoyles, L., McCartney, A. L., Rastall, R., Rowland, I., Wolvers, D., Watzl, B., Szajewska, H., & Stahl, B. (2010). Prebiotic effects: metabolic and health benefits. *British Journal of Nutrition*, *104*(S2), S1-S63.

San Andres, J. V. (2020). *Bio-Stimulants Effects on Growth Performance and Gut Health of Nursery Pigs* The University of Nebraska-Lincoln].

Shreiner, A. B., Kao, J. Y., & Young, V. B. (2015). The gut microbiome in health and in disease. *Current opinion in gastroenterology*, *31*(1), 69-75.

Tilg, H., & Kaser, A. (2011). Gut microbiome, obesity, and metabolic dysfunction. *The Journal of clinical investigation*, *121*(6), 2126-2132.

Turnbaugh, P. J., Hamady, M., Yatsunenko, T., Cantarel, B. L., Duncan, A., Ley, R. E., Sogin, M. L., Jones, W. J., Roe, B. A., & Affourtit, J. P. (2009). A core gut microbiome in obese and lean twins. *nature*, *457*(7228), 480-484.

Vandeputte, D., Falony, G., Vieira-Silva, S., Wang, J., Sailer, M., Theis, S., Verbeke, K., & Raes, J. (2017). Prebiotic inulin-type fructans induce specific changes in the human gut microbiota. *Gut*, *66*(11), 1968-1974.

Wu, H.-J., & Wu, E. (2012). The role of gut microbiota in immune homeostasis and autoimmunity. *Gut microbes*, *3*(1), 4-14.

Zakrzewska, Z., Zawartka, A., Schab, M., Martyniak, A., Skoczeń, S., Tomasik, P. J., & Wędrychowicz, A. (2022). Prebiotics, probiotics, and postbiotics in the prevention and treatment of anemia. *Microorganisms*, *10*(7), 1330.

Żółkiewicz, J., Marzec, A., Ruszczyński, M., & Feleszko, W. (2020). Postbiotics—a step beyond pre-and probiotics. *Nutrients*, *12*(8), 2189.